Convoke is building the AI-native operating system for drug development.
Planning and executing a modern drug launch is one of humanity’s most cognitively complex coordination tasks—not unlike a rocket launch.
Biopharma companies must pull together information from thousands of point solutions, share it across hundreds of siloed contributors inside and outside of their organizations, all while keeping everything up to date.
In aggregate, this information processing burden is a meaningful drag on industry productivity. However, advances in machine learning can empower teams to learn and iterate faster—to move at the speed of silicon, not humans.
Our vision is to build an autonomous system that shepherds the next generation of drugs to market. We believe that as new platforms and modalities proliferate and commodify—and our ability to control human biology democratizes—what will ultimately differentiate drug programs will not be their chemical matter, but how they are developed.
If we succeed, we will significantly increase society’s capacity to bring new drugs to market.
Backed by Leading Investors
And others, including ACME, Liquid2, Audacious, Comma Capital, Not Boring Capital, Lux Capital, and angels including Qasar Younis, Erik Torenberg, and others leaders in AI and biotechnology.
Help us increase society's capacity to bring medicines to patients
If you are excited about working at the intersection of artificial intelligence and biotechnology, we want to hear from you
